Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)

NCT01812252 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01812252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01812252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 19, 2013
Completion date
October 26, 2022
Enrollment
50 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, myelodysplastic syndrome, secondary myelodysplastic syndrome